ExploreWatchlistsPricing
  1. JP-listed companies
  2. OncoTherapy Science, Inc.
  3. Financials
  4. Pretax margin (%)

OncoTherapy Science, Inc. (4564)

Market cap
¥6.4B
P/E ratio
OncoTherapy Science develops cancer treatments using genetic research, including targeted drugs, immunotherapies, and precision medicine testing for personalized cancer care.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndPretax margin (%) YoY (%)
Mar 31, 2025-108.7-41.66%
Mar 31, 2024-186.3+86.55%
Mar 31, 2023-99.8-44.40%
Mar 31, 2022-179.6-63.58%
Mar 31, 2021-493-29.04%
Mar 31, 2020-694.8-34.11%
Mar 31, 2019-1,054.6-25.17%
Mar 31, 2018-1,409.3+34.28%
Mar 31, 2017-1,049.5-5.46%
Mar 31, 2016-1,110.2+340.63%
Mar 31, 2015-251.9-31.94%
Mar 31, 2014-370.2+989.13%
Mar 31, 2013-34-268.45%
Mar 31, 201220.2

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat